Hester Biosciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 09, 2025.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences reported audited FY25 results with standalone revenue of ₹2,864.66 million (up ~0.5% from ₹2,851.55 million in FY24) and standalone profit after tax of ₹318.42 million (up ~17% from ₹271.59 million). Consolidated revenue grew ~2% to ₹3,111.02 million, while consolidated PAT jumped ~36% to ₹288.26 million. Q4 standalone PAT rose ~30% YoY to ₹96.35 million on revenue of ₹766.72 million. The board has recommended a dividend of ₹7 per share (70%) for FY25, subject to shareholder approval. Statutory auditor Chandulal M. Shah & Co. issued an unmodified (clean) opinion on both standalone and consolidated results.
The clean audit opinion, solid Q4 profit growth, and continued dividend payout are positive signals for shareholders. However, near-flat standalone revenue growth suggests top-line pressure, even as profitability improved. Segment data was restated with Petcare merged into Animal Healthcare, which changes prior-period comparisons.